Of those, Alva et al. [14] demonstrated that treatment with the full six cycles of 223Ra therapy was associated with an ECOG performance status of 0–1, no or mild pain, lower PSA, normal AP, no prior Abiraterone–Enzalutamide therapy, and low BSI, a parameter of bone tumor burden. Here, KLK3 is linked to bone neoplasm.